# Invivyd, Inc.: overview IVVD · Nasdaq · CIK 1832038 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ivvd.md) · [Financials](/companies/ivvd/financials.md) · [Filings](/companies/ivvd/filings.md) · [Insiders](/companies/ivvd/insiders.md) Latest reported revenue: [$14.3m](/filings/0001193125-26-349215.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-349215). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [9.3](/filings/0001193125-25-268076.md) | [13.8 d](/filings/0001193125-26-092547.md) | [11.3](/filings/0001193125-26-222779.md) | [11.8](/filings/0001193125-26-349215.md) | [13.1](/filings/0001193125-25-268076.md) | [17.2 d](/filings/0001193125-26-092547.md) | [13.7](/filings/0001193125-26-222779.md) | [14.3](/filings/0001193125-26-349215.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(670.0%)](/filings/0001193125-25-268076.md) | [(139.1%) d](/filings/0001193125-26-092547.md) | [(149.7%)](/filings/0001193125-26-222779.md) | [(127.8%)](/filings/0001193125-26-349215.md) | [(84.0%)](/filings/0001193125-25-268076.md) | [(73.0%) d](/filings/0001193125-26-092547.md) | [(313.9%)](/filings/0001193125-26-222779.md) | [(320.8%)](/filings/0001193125-26-349215.md) | | Net margin | % | [(653.1%)](/filings/0001193125-25-268076.md) | [(133.5%) d](/filings/0001193125-26-092547.md) | [(144.1%)](/filings/0001193125-26-349215.md) | [(124.4%)](/filings/0001193125-26-349215.md) | [(79.7%)](/filings/0001193125-25-268076.md) | [(64.3%) d](/filings/0001193125-26-092547.md) | [(301.2%)](/filings/0001193125-26-349215.md) | [(310.8%)](/filings/0001193125-26-349215.md) | | Diluted EPS | $ per share | [(0.51)](/filings/0001193125-25-268076.md) | not reported | [(0.14)](/filings/0001193125-26-222779.md) | [(0.12)](/filings/0001193125-26-349215.md) | [(0.06)](/filings/0001193125-25-268076.md) | not reported | [(0.13)](/filings/0001193125-26-222779.md) | [(0.14)](/filings/0001193125-26-349215.md) | | Free cash flow | $m | [(41.1) d](/filings/0001193125-25-268076.md) | [(37.6) d](/filings/0001193125-26-092547.md) | [(21.3)](/filings/0001193125-26-222779.md) | [(13.3) d](/filings/0001193125-26-349215.md) | [(8.3) d](/filings/0001193125-25-268076.md) | [(15.5) d](/filings/0001193125-26-092547.md) | [(42.4)](/filings/0001193125-26-222779.md) | [(43.5) d](/filings/0001193125-26-349215.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [0.0](/filings/0000950170-25-042332.md) | [25.4](/filings/0001193125-26-092547.md) | [53.4](/filings/0001193125-26-092547.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [(696.8%)](/filings/0001193125-26-092547.md) | [(104.0%)](/filings/0001193125-26-092547.md) | | Net margin | % | not reported | not reported | not reported | [(669.4%)](/filings/0001193125-26-092547.md) | [(98.2%)](/filings/0001193125-26-092547.md) | | Diluted EPS | $ per share | [(5.32)](/filings/0000950170-23-009516.md) | [(2.23)](/filings/0000950170-24-037610.md) | [(1.81)](/filings/0000950170-25-042332.md) | [(1.43)](/filings/0001193125-26-092547.md) | [(0.30)](/filings/0001193125-26-092547.md) | | Free cash flow | $m | [(185)](/filings/0000950170-23-009516.md) | [(222)](/filings/0000950170-24-037610.md) | [(174)](/filings/0000950170-25-042332.md) | [(171)](/filings/0001193125-26-092547.md) | [(58.3)](/filings/0001193125-26-092547.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ivvd/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $42.9m | 33,094,330 | | Not compared | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $30.0m | 34,173,104 | | Not compared | | [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $24.6m | 28,165,000 | | Added +8,640,000 | | [MAVERICK CAPITAL LTD](/funds/934639.md) | 2026-06-30 | $16.6m | 18,970,913 | | Unchanged | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $16.1m | 18,490,636 | | Reduced −2,368,667 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $14.1m | 16,134,885 | | Added +11,853,095 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $9.2m | 10,496,507 | | Added +422,181 | | [M28 Capital Management LP](/funds/1807489.md) | 2026-06-30 | $8.1m | 9,248,250 | | Unchanged | | [Saturn V Capital Management LP](/funds/1964437.md) | 2026-06-30 | $7.3m | 8,392,288 | | Reduced −2,556,796 | | [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $6.7m | 7,708,727 | | Unchanged | ## Recent filings [All 447 filings](/companies/ivvd/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-29 | 03:26 ET | [8-K](/filings/0001193125-26-406007.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-406007 | | 2026-09-01 | 07:10 ET | [8-K](/filings/0001193125-26-377493.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-377493 | | 2026-08-13 | 16:14 ET | [10-Q](/filings/0001193125-26-349215.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349215 | | 2026-08-13 | 16:11 ET | [8-K](/filings/0001193125-26-349193.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-349193 | | 2026-07-24 | 16:05 ET | [8-K](/filings/0001193125-26-316066.md) | 3.01 Delisting notice | 0001193125-26-316066 | | 2026-07-06 | 07:11 ET | [8-K](/filings/0001193125-26-295539.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-295539 | | 2026-05-19 | 16:05 ET | [8-K](/filings/0001193125-26-230731.md) | 5.07 Shareholder vote results | 0001193125-26-230731 | | 2026-05-14 | 07:18 ET | [10-Q](/filings/0001193125-26-222779.md) | Quarterly report, period 2026-03-31 | 0001193125-26-222779 | | 2026-05-14 | 07:12 ET | [8-K](/filings/0001193125-26-222762.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-222762 | | 2026-04-09 | 07:13 ET | [8-K](/filings/0001193125-26-148865.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-148865 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-092547.md), filed Mar 5, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9f86f621-55fd-4ed4-8bdd-ea32a954b777) ## About the filer - CIK: 1832038 - Tickers: IVVD - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.